Floatz logo

DFN-11 (SUMATRIPTAN INJECTION)

Headache Disorder

Danish Headache CenterSmall moleculePhase 4 / ApprovedActive
BBB
75/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
66/ 100
Competitive Position
89/ 100

Competitive context

12 Active assets in the Headache Disorder cohort.

Asset / SponsorPhaseRating
Topiramate
University of Minnesota
Phase 4BBB
Lidocaine
Daniel A Tonetti, MD
Phase 4BBB
Prochlorperazine
Wake Forest University Health Sciences
Phase 4BBB
Marcaine
HCA Florida North Florida Hospital
Phase 4BBB
PROPOFOL
Medical College of Wisconsin
Phase 4BBB

View all 50 →

Same molecule, other indications

DFN-11 (SUMATRIPTAN INJECTION) is also rated in:

migraine disorderActive
BBB
Indicative · Phase 4
79 / 100
View asset →
migraine with auraActive
BB
Indicative · Phase 3
67 / 100
View asset →
migraine without auraActive
BB
Indicative · Phase 3
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →